Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Change in Inventory (2020 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Change in Inventory for 6 consecutive years, with -$560658.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory rose 20.39% year-over-year to -$560658.0, compared with a TTM value of -$254714.0 through Dec 2025, down 179.05%, and an annual FY2025 reading of -$398348.0, down 143.85% over the prior year.
  • Change in Inventory was -$560658.0 for Q4 2025 at Neuroone Medical Technologies, down from $331604.0 in the prior quarter.
  • Across five years, Change in Inventory topped out at $841721.0 in Q3 2024 and bottomed at -$704292.0 in Q4 2024.
  • Average Change in Inventory over 5 years is $90220.3, with a median of $164922.0 recorded in 2021.
  • The sharpest move saw Change in Inventory skyrocketed 3854.2% in 2023, then plummeted 496.71% in 2024.
  • Year by year, Change in Inventory stood at $130828.0 in 2021, then surged by 52.12% to $199016.0 in 2022, then crashed by 159.31% to -$118029.0 in 2023, then tumbled by 496.71% to -$704292.0 in 2024, then rose by 20.39% to -$560658.0 in 2025.
  • Business Quant data shows Change in Inventory for NMTC at -$560658.0 in Q4 2025, $331604.0 in Q3 2025, and $70594.0 in Q2 2025.